Q4: -6% org. sales growth, 2% adj. EBITA growth, strong cash flow '25e-'26e adj.
Sales 0% and adj. EBIT +13% vs. ABGSCe Operating cash flow SEK 98m, vs ABGSCe SEK 6m Minor positive ...
Redeye shares its initial take on Kontigo Care’s Q4 2024 results, which showed sales and monthly rec...
Redeye comments on WntResearch’s conditional reverse acquisition of OPSY AB.
Vitrolife delivered a consecutive positive organic growth recovery with 6% organic growth in constan...
Redeye provides an initial comment on Addnode’s Q4 report, showing solid numbers in all three Divisi...
Redeye provides its initial take on MedCap’s Q4 2024 report, which came in broadly below our initial...
Redeye updates on Evolution following Q4-results which were in with our forecasts.
Sales -3%, adj. EBIT -2m vs. ABGSCe Temporary incoming delivery delays push cash flow into Q1 Optimi...
Redeye comments on further news from the all-important US market.
Redeye finetunes its forecasts for 2025 and beyond following Fortnox’s price increases.
Redeye comments on Enea’s Q4 2024 report, where sales met Redeye Research estimates (RRe) in Enea’s ...
Redeye comments on Evolution’s Q4-results which were in line with our forecasts.
Redeye offers a preview of Doro's Q4 results set to be released on February 13.
We lower adjusted EBITA by 5% for 2025E-27E following the Q4 report.
Nosa Plugs AB (”Nosa Plugs” eller ”Bolaget”) meddelade den 29 januari år 2025 att Bolaget har knutit...
Redeye is encouraged by the recent news regarding Integrum’s increased educational activities, toget...
38% y-o-y sales growth for Catalyst in Q4'24e We leave our EBIT forecasts unchanged ahead of the rep...
On January 29th, Eevia Health Plc (publ) (“Eevia”) announced ten new sales orders for products total...